Gilead Sciences (NASDAQ:GILD) Price Target Raised to $190.00

Gilead Sciences (NASDAQ:GILD) had its price target upped by JPMorgan Chase & Co. from $170.00 to $190.00 in a report issued on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Zacks Research cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $184.00 target price on shares of Gilead Sciences in a research note on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Gilead Sciences Price Performance

NASDAQ GILD opened at $170.68 on Friday. The business has a 50 day simple moving average of $150.87 and a 200 day simple moving average of $139.79. The stock has a market cap of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.35. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.95 and a current ratio of 1.32. Gilead Sciences has a 52-week low of $114.02 and a 52-week high of $175.65.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.47 earnings per share. Analysts anticipate that Gilead Sciences will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Insiders Place Their Bets

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 96,000 shares of company stock valued at $13,923,210 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Client 1ST Advisory Group LLC increased its stake in shares of Gilead Sciences by 4.0% in the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 69 shares during the last quarter. Bfsg LLC boosted its position in shares of Gilead Sciences by 7.7% in the 3rd quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 72 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Gilead Sciences by 1.2% in the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after purchasing an additional 74 shares during the period. Financial Connections Group Inc. lifted its holdings in Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 76 shares in the last quarter. Finally, Wilkerson Advisory Group LLC grew its holdings in Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.